Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
https://doi.org/10.4084/MJHID.2026.047

COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: April 30, 2026
0
Views
0
Downloads
0
HTML
Systemic mastocytosis, Lymphoproliferative disease

Authors

Antonio Frolli
antonio.frolli@unito.it
Division of Hematology, AO Ordine Mauriziano di Torino, Italy.
Cristina Papayannidis
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. e A. Seràgnoli, Bologna, Italy, Italy.
Carmen Fava
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Martina Bullo
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Selene Grano
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Valentina Bonuomo
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Daniela Gottardi
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Guido Parvis
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.
Beatrice Casadei
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. e A. Seràgnoli, Bologna, Italy, Italy.
Daniela Cilloni
Division of Hematology, AO Ordine Mauriziano di Torino, Torino, Italy, Italy.

While systemic mastocytosis (SM) is well-established in its association with myeloid neoplasms, its concurrent occurrence with lymphoproliferative disorders is exceedingly rare and poorly characterized. We report a multicenter retrospective series of 9 patients diagnosed with both SM and lymphoma according to WHO 2022 criteria.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 15 settembre 2022;140(11):1200–28. doi:10.1182/blood.2022015850 PubMed PMID: 35767897; PubMed Central PMCID: PMC9479031.
2. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere. novembre 2021;5(11):e646. doi:10.1097/HS9.0000000000000646
3. Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. luglio 2023;98(7):1097–116. doi:10.1002/ajh.26962 PubMed PMID: 37309222.
4. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. luglio 2022;36(7):1703–19. doi:10.1038/s41375-022-01613-1
5. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 16 marzo 2017;129(11):1420–7. doi:10.1182/blood-2016-09-731893 PubMed PMID: 28031180; PubMed Central PMCID: PMC5356454.
6. Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. maggio 2015;29(5):1115–22. doi:10.1038/leu.2015.4 PubMed PMID: 25567135.
7. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 13 novembre 2018;2(21):2964–72. doi:10.1182/bloodadvances.2018026245 PubMed PMID: 30413432; PubMed Central PMCID: PMC6234360.
8. Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. gennaio 2016;30(1):136–43. doi:10.1038/leu.2015.284 PubMed PMID: 26464169.
9. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 3 ottobre 2013;122(14):2460–6. doi:10.1182/blood-2013-04-496448 PubMed PMID: 23958953.
10. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. gennaio 2014;28(1):78–87. doi:10.1038/leu.2013.269 PubMed PMID: 24045501.
11. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. ottobre 2014;69(10):1267–74. doi:10.1111/all.12436 PubMed PMID: 24836395.
12. Iqbal MF, Soriano PMK, Nagendra S, Sana S. Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma. Am J Case Rep. 3 ottobre 2017;18:1053–7. doi:10.12659/ajcr.905759 PubMed PMID: 28970467; PubMed Central PMCID: PMC5637574.
13. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 23 aprile 2010;3(4):448–57. PubMed PMID: 20490336; PubMed Central PMCID: PMC2872752.
14. Hauswirth AW, Födinger M, Fritz M, Müllauer L, Simonitsch-Klupp I, Streubel B, et al. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Hum Pathol. giugno 2008;39(6):917–24. doi:10.1016/j.humpath.2007.10.022 PubMed PMID: 18448146.
15. Horny HP, Sotlar K, Stellmacher F, Valent P, Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol. marzo 2006;59(3):264–8. doi:10.1136/jcp.2005.026989 PubMed PMID: 16505276; PubMed Central PMCID: PMC1860346.
16. Ault P, Lynn A, Tam CS, Medeiros LJ, Keating MJ. Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis. Leuk Res. dicembre 2007;31(12):1755–8. doi:10.1016/j.leukres.2007.04.002 PubMed PMID: 17521719.
17. Fernández-Torres R, Verea MM, Álvarez A, Torres P, Fonseca E. Systemic Mastocytosis Associated with Splenic Marginal Zone Lymphoma with Villous Lymphocytes. Dermatol Res Pract. 2011;2011:385074. doi:10.1155/2011/385074 PubMed PMID: 21785582; PubMed Central PMCID: PMC3137984.
18. Meyer KM, Landthaler M, Hafner C, Geissinger E. Systemic mastocytosis associated with cutaneous B-cell lymphoma. Br J Dermatol. novembre 2013;169(5):1165–7. doi:10.1111/bjd.12471 PubMed PMID: 23773144.
19. Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, et al. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. agosto 2022;10(8):1953–63. doi:10.1016/j.jaip.2022.03.001 PubMed PMID: 35283331.
20. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Cancer Netw JNCCN. ottobre 2025;23(10):e250048. doi:10.6004/jnccn.2025.0048 PubMed PMID: 41067277.
21. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol. 20 settembre 2014;32(27):3059–68. doi:10.1200/JCO.2013.54.8800 PubMed PMID: 25113753; PubMed Central PMCID: PMC4979083.
22. Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, et al. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. agosto 2022;10(8):2025-2038.e1. doi:10.1016/j.jaip.2022.05.034 PubMed PMID: 35724948.
23. Schipper EM, Posthuma W, Snieders I, Brouwer RE. Mastocytosis and diffuse large B-cell lymphoma, an unlikely combination. Neth J Med. marzo 2011;69(3):132–4. PubMed PMID: 21444939.
24. John MV, Simonitsch-Klupp I, Griss J, Waldstein C, Herrmann H, Gaiger A, et al. Bone marrow mastocytosis associated with primary cutaneous follicle center lymphoma: an unusual case report. Ann Hematol. ottobre 2025;104(10):5543–8. doi:10.1007/s00277-025-06588-4 PubMed PMID: 40913208; PubMed Central PMCID: PMC12619747.
25. Sanz MA, Valcárcel D, Sureda A, Muñoz L, Espinosa I, Nomdedeu J, et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica. ottobre 2001;86(10):1106–7. PubMed PMID: 11602421.
26. Zagaria A, Anelli L, Coccaro N, Tota G, Brunetti C, Minervini A, et al. Systemic Mastocytosis with Associated Chronic Lymphocytic Leukemia: A Matter of Diseases or Prognostic Factors? Turk J Haematol Off J Turk Soc Haematol. 2 agosto 2017;34(3):276–7. doi:10.4274/tjh.2017.0014 PubMed PMID: 28351827; PubMed Central PMCID: PMC5544054.
27. Lee HY, Lee JS, Koo DW. A case report of primary cutaneous marginal zone B-cell lymphoma with mastocytosis. SAGE Open Med Case Rep. 2021;9:2050313X211042527. doi:10.1177/2050313X211042527 PubMed PMID: 34471539; PubMed Central PMCID: PMC8404676.
28. Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, et al. Mast cells in Waldenstrom’s macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol Off J Eur Soc Med Oncol. agosto 2006;17(8):1275–82. doi:10.1093/annonc/mdl109 PubMed PMID: 16788002.
29. Frederiksen JK, Shao L, Bixby DL, Ross CW. Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray-based whole-genome scanning. Genes Chromosomes Cancer. aprile 2016;55(4):389–96. doi:10.1002/gcc.22342 PubMed PMID: 26865278.
30. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. aprile 2010;220(5):586–95. doi:10.1002/path.2677 PubMed PMID: 20112369.
31. Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. marzo 2013;88(3):219–24. doi:10.1002/ajh.23380 PubMed PMID: 23440662; PubMed Central PMCID: PMC4188390.
32. Kim Y, Weiss LM, Chen YY, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res. dicembre 2007;31(12):1749–54. doi:10.1016/j.leukres.2007.04.008 PubMed PMID: 17544505.
33. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 21 giugno 2018;131(25):2745–60. doi:10.1182/blood-2017-09-806398 PubMed PMID: 29540348.
34. Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. gennaio 2020;31(1):17–29. doi:10.1016/j.annonc.2019.10.010 PubMed PMID: 31912792.
35. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 1 febbraio 2013;119(3):629–38. doi:10.1002/cncr.27773 PubMed PMID: 22893605.
36. Abuhelwa Z, Beran A, Kahlon N, Sayeh W, Khokher W, Assaly R, et al. Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis. Am J Ther. 1 dicembre 2023;30(6):e573–5. doi:10.1097/MJT.0000000000001508 PubMed PMID: 35446286.
37. DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. febbraio 2018;32(2):470–8. doi:10.1038/leu.2017.234 PubMed PMID: 28744009.
38. DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. dicembre 2021;27(12):2183–91. doi:10.1038/s41591-021-01538-9 PubMed PMID: 34873347; PubMed Central PMCID: PMC8674134.
39. Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. dicembre 2021;27(12):2192–9. doi:10.1038/s41591-021-01539-8 PubMed PMID: 34873345; PubMed Central PMCID: PMC8674139.
40. Costanzo G, Marzio V, Cavaglià E, Paoletti G, Heffler E. New treatments for systemic mastocytosis in 2025. Curr Opin Allergy Clin Immunol. agosto 2025;25(4):277. doi:10.1097/ACI.0000000000001079

Ethics Approval

Systemic mastocytosis, B-Cell Lymphoproliferative disorders (B-LPDs)

Supporting Agencies

NONE

How to Cite



“COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026047. doi:10.4084/MJHID.2026.047.
Copyright (c) 2026 Antonio Frolli, Cristina Papayannidis, Carmen Fava, Martina Bullo, Selene Grano, Valentina Bonuomo, Daniela Gottardi, Guido Parvis, Beatrice Casadei, Daniela Cilloni Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.